Core Viewpoint - The company, Yidu Technology (02158), has been actively repurchasing its shares, indicating confidence in its stock value and financial health. Additionally, the approval of a new drug for infant vascular tumors highlights the company's role in supporting pharmaceutical development through market research and analysis services [1]. Share Buyback Activity - On October 14, Yidu Technology repurchased 1.4728 million shares at a price range of HKD 5.75 to HKD 5.99 per share, totaling HKD 8.58 million [1]. - Since September 26, the company has conducted four share buybacks, accumulating a total of 3.1916 million shares repurchased, with a total expenditure of HKD 18.6359 million [1]. Drug Approval and Market Support - The company provided critical market research and project analysis services for the recently approved topical treatment, Timolol Maleate Gel, which is the first drug targeting proliferative superficial infantile hemangiomas [1].
医渡科技半月4次回购近320万股 耗资约1860万港元